- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2022–2027 · research · R01
Genomic and Genomic Variation in Prostate Cancer
Timothy Richard Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Genomic and Genomic Variation in Prostate Cancer
Timothy Richard Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Elucidating the molecular mechanism and physiological relevance of TIRR mediated inhibition of p53
Dipanjan Chowdhury · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
Tracing the Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome: Defining Transformation
Erin M Parry · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · career development · K00
Targeting Oncogenic Drivers in Cancer
Matthew W Boudreau · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · cooperative agreement · U01
Molecular prediction of myeloma in African Americans
Catherine Marinac · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers
Geoffrey I. Shapiro · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · research · R01
Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs
Eric Sebastian Fischer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
Regulation and targeting of tumor cell states and plasticity in pancreatic cancer
Srivatsan Raghavan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Genomic and Genomic Variation in Prostate Cancer
Timothy Richard Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Engineering dendritic cells to target islet antigen to pro-tolerogenic subsets for prevention and treatment of Type 1 Diabetes
Judith Agudo Cantero · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Promoting Resilience in Early Survivorship among Adolescents and Young Adults with Cancer
Abby R Rosenberg · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Investigating and modeling MYD88L265P and co-occurring mutations in mature B-cell malignancies
Ruben D Carrasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Admin Core
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Project 3
Pasi A Janne · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Biostatistics and Data Management
Haesook T Kim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Metabolomics of cGVHD
Bruce R Blazar · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2024 · program · P01
Immune Modulation After Allogeneic HCT
Robert Jon Soiffer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Admin Core
Corey S Cutler · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Biobanking and Immunologic Monitoring
Jerome Ritz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Admin Core
Corey S Cutler · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Project 1
Mark M. Awad · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Biostatistics Core
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Single Cell Analysis and Immunogenetics
Kenneth James Livak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Project 2
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Project 2
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Developmental Research Program
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Metabolomics of cGVHD
Bruce R Blazar · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Admin Core
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Career Enhancement Program
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Developmental Research Program
Rebecca Suk Heist · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Pathology & Genomics
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Biostatistics and Data Management
Haesook T Kim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Bronchiolitis Obliterans: Discovery and Therapy
Corey S Cutler · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2024 · cooperative agreement · U54
Administrative Core
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Pathology & Genomics
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Single Cell Analysis and Immunogenetics
Kenneth James Livak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Biobanking and Immunologic Monitoring
Jerome Ritz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Defining the T Cell Mediators of Clinical Response in Chronic GVHD
Leslie S Kean · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Project 3
Pasi A Janne · Dana-Farber Cancer Institute · funded by National Institutes of Health
